The former depend on exogenous insulin therapy for survival, while many people with type 2 diabetes will eventually—in addition to oral hypoglycaemic agents—require insulin as a consequence of relative insulin deficiency that worsens with disease progression [7, 8]. This evidence concerns the gene INS and type 2 diabetes mellitus.